Perioperative dexmedetomidine improves mortality in patients undergoing coronary artery bypass surgery.

ABSTRACT:

Objective

This study retrospectively investigated the effect of dexmedetomidine on outcomes of patients undergoing coronary artery bypass graft (CABG) surgery.

Design

Retrospective investigation.

Setting

Patients from a single tertiary medical center.

Participants

A total of 724 patients undergoing CABG surgery met the inclusion criteria and were categorized into 2 groups: 345 in the dexmedetomidine group (DEX) and 379 in the nondexmedetomidine group (Non-DEX).

Interventions

Perioperative dexmedetomidine was used as an intravenous infusion (0.24 to 0.6 µg/kg/hour) initiated after cardiopulmonary bypass and continued for less than 24 hours postoperatively in the intensive care unit.

Measurements and main results

Major outcome measures of this study

SUBMITTER: Ji F 

PROVIDER: S-EPMC4402998 | biostudies-literature | 2014 Apr

REPOSITORIES: biostudies-literature